Long-term real-world outcomes of first-line immunotherapy in non-small cell lung cancer - a population-based cohort study in Sweden.

ABSTRACT:

Background

In a previous study, we explored real-world programmed death-ligand 1 (PD-L1) testing and treatment patterns for patients with advanced non-small cell lung cancer (NSCLC) in the era of immune-oncology. The present study aimed to investigate overall survival (OS) with PD-(L)1 inhibitors with longer-term follow-up in the Swedish setting.

Materials and methods

Data were extracted from the Swedish National Lung Cancer Registry for patients with NSCLC stage IIIB-IV and ECOG performance status (PS) 0-2 who initiated first-line systemic treatment from 1-April-2017 to 30-June-2021 with data cut-off 30-June-2022. OS and Kaplan-Meier estimates were calculated from start of the PD-(L)1 inhibitor therapy, with subgroups based on nonsquamous/squamous (NSQ/SQ) histology, and fu

SUBMITTER: Wagenius G 

PROVIDER: S-EPMC11931854 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature